Extended Data Fig. 5: Proportion of participants with detectable HIV RNA in plasma after each dose.
We measured plasma viral load (pVL) pre-dose 1 and again at 8, 12, and 24 hours after each dose and again at day 4. At the pre-dose 1 measure, only 1/11 (9.1%) had a detectable pVL (<20 copies/ml) and of the 132 samples obtained during follow-up, 30 (22.7%) had detectable HIV RNA in 10/11 (91%) participants. Of the positive measurements, 3 were greater than 20 copies/ml (23, 30, 35 copies/ml) and the remaining were reported as HIV RNA detected but < 20 copies/ml. These data are consistent with small transient increases in HIV transcription in the peripheral blood compartment associated with N-803 administration.
